Presentation on theme: "Arthritis Foundation Arthritis Ambassador Briefing September 11, 2013 3PM Eastern Dial In: 1-866-487-9460 Participant Code: 931 709 2991# Materials available."— Presentation transcript:
Arthritis Foundation Arthritis Ambassador Briefing September 11, PM Eastern Dial In: Participant Code: # Materials available for download at
Agenda Welcome & August Recap – Laurie Markle, Manager Grassroots Advocacy Ambassador Experience– Hanna Gruen (PA-14) How Limiting Cost Sharing for Specialty Drugs would Impact Insurance Premiums- Maria Spencer, Director Federal Affairs September Ambassador Assignment– Laurie Markle Reporting Your Activity– Laurie Markle Housekeeping– Laurie Markle Q&A 1
August Recess Recap 2 CosponsorsAwareness Pass HR 1827
August Recess Recap 3 33 Congressional Meetings & Town Halls Results pending. to follow.
Ambassador Experience On the phone: Hanna Gruen, PA-14 Ambassador 4
HR 460 Impact on Premiums 5 The Problem: Health insurance companies are placing vital, life- changing and life-saving medications including biologics on specialty tiers and charging a co-insurance or percentage of the cost of the drug, instead of a copay. This practice is placing a substantial financial burden on patients. Some patients may pay hundreds or thousands of dollars per month for a medication that was traditionally on a fixed co-pay.
HR 460 Impact on Premiums 6 The Solution: The Patients’ Access to Treatments Act (H.R. 460): Requires plans to limit cost sharing requirements for specialty drug tiers to the level of cost sharing required for non-preferred brand drug tiers; there can be no more than a 10% difference in total dollar cost sharing for any drugs on a tier. Drug TypeExample Patient Out-of-Pocket Expense Tier 1: Generic$10 Tier 2: Preferred Brand Name$30 Tier 3: Nonpreferred Brand Name$50 (limits range to 10%: $50-55) Tier 4: Specialty Tier DrugCost sharing can be no greater than Tier 3 out of pocket expense.
HR 460 Impact on Premiums 7 Arthritis Foundation and 22 other organizations formed the Coalition for Accessible Treatments (CAT) in support of the Patients’ Access to Treatments Act (H.R. 460) CAT commissioned a study to address Congressional concerns about PATA’s impact on premiums. Study Conclusion: Limiting Specialty Drug Coinsurance does not have a large impact on premiums. The bill would increase premium costs by $3 per year, absent any other changes to the average benefit design.
HR 460 Impact on Premiums 8 What are we doing? CAT hosted a press conference to release study results Sept. 10 th CAT will host a Senate briefing Sept. 19 th Goal: gain additional co-sponsors in the House; Senate bill introduced
September Ambassador Assignment 9 SUNDAYMONDAYTUESDAYWEDNESDAYTHURSDAYFRIDAYSATURDAY PRESS EVENT AMBASSADOR BRIEFING SENATE BRIEFING CALLS & S CALLS & EMALS CALLS & S CALLS & S CALLS & EMALS CALLS & S CALLS & S We need Senate Health Legislative Assistants at the Briefing on September 19 th!
September Ambassador Assignment 10 Call your Senate Health Legislative Assistants and request their attendance at the September 19 th Briefing If you leave a message and don’t hear back within 3 days, them. Report POSITIVE RSVPs to Geoff Steber at Report your activity to arthritis.org/report
September Assignment: First Steps 11 Identify your 2 Senate.gov Visit your Senator’s website and identify their DC phone bottom of page Call and ask to speak with the Health Legislative Assistant. Share prepared voic . Follow up with an . If you don’t know the address, or
September Ambassador Assignment Accessing the resources you need 12
Reporting Your Activity POSTIVE RSVPs should be reported to Geoff Steber at Report your activity & receive credit at Username: Your address Password: Last Name 16
Housekeeping Remaining Ambassador Briefings: October 2, 3PM Eastern November 6, 3PM Eastern Ambassador Awards are awarded annually based on activity reported October-October Award recipients will be announced at the November 6 th briefing. 17